Consecutive CT in vivo lung imaging as quantitative parameter of influenza vaccine efficacy in the ferret model.

Preclinical vaccine efficacy studies are generally limited to certain read out parameters such as assessment of virus titers in swabs and organs, clinical signs, serum antibody titers, and pathological changes. These parameters are not always routinely applied and not always scheduled in a logical standardized way. We used computed tomography (CT) imaging as additional and novel read out parameter in a vaccine efficacy study by quantifying alterations in aerated lung volumes in ferrets challenged with the 2009 pandemic A/H1N1 influenza virus. Vaccination protected from marked variations in aerated lung volumes compared to naive controls. The vaccinated group showed a daily gradual mean reduction with a maximum of 7.8%, whereas the controls showed a maximum of 14.3% reduction. The pulmonary opacities evident on CT images were most pronounced in the placebo-treated controls, and corresponded to significantly increased relative lung weights at necropsy. This study shows that consecutive in vivo CT imaging allows for a day to day read out of vaccine efficacy by quantification of altered aerated lung volumes.

[1]  R. Compans,et al.  Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection against 2009 H1N1 Pandemic Influenza , 2011, Clinical and Vaccine Immunology.

[2]  T. Kuiken,et al.  Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. , 2011, Vaccine.

[3]  A. Osterhaus,et al.  Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. , 2011, Vaccine.

[4]  T. Kuiken,et al.  Immunization of Macaques with Formalin-Inactivated Respiratory Syncytial Virus (RSV) Induces Interleukin-13-Associated Hypersensitivity to Subsequent RSV Infection , 2002, Journal of Virology.

[5]  Xiufan Liu,et al.  Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. , 2011, Vaccine.

[6]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[7]  M. Kieny,et al.  Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. , 2011, Vaccine.

[8]  T. Kuiken,et al.  Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. , 2011, The American journal of pathology.

[9]  C. Black Systematic review of the biology and medical management of respiratory syncytial virus infection. , 2003, Respiratory care.

[10]  D. Weiner,et al.  Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. , 2011, Vaccine.

[11]  Thomas P. Fabrizio,et al.  Contemporary Seasonal Influenza A (H1N1) Virus Infection Primes for a More Robust Response To Split Inactivated Pandemic Influenza A (H1N1) Virus Vaccination in Ferrets , 2010, Clinical and Vaccine Immunology.

[12]  R. Rappuoli,et al.  Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization , 2009, Science Translational Medicine.

[13]  Ron A M Fouchier,et al.  Severity of Pneumonia Due to New H1N1 Influenza Virus in Ferrets Is Intermediate between That Due to Seasonal H1N1 Virus and Highly Pathogenic Avian Influenza H5N1 Virus , 2010, The Journal of infectious diseases.

[14]  T. Kuiken,et al.  Pulmonary pathology of pandemic influenza A/H1N1 virus (2009)-infected ferrets upon longitudinal evaluation by computed tomography , 2011, The Journal of general virology.

[15]  Hideo Goto,et al.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses , 2009, Nature.

[16]  C. J. Martel,et al.  CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets , 2011, PloS one.

[17]  K. Subbarao,et al.  Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. , 2011, The Journal of infectious diseases.

[18]  M. Salazar,et al.  Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. , 2011, Vaccine.

[19]  T. Tumpey,et al.  Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. , 2011, Vaccine.

[20]  Marion Koopmans,et al.  Pathogenesis and Transmission of Swine-Origin 2009 A(H1N1) Influenza Virus in Ferrets , 2009, Science.